Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2024 May 23;14:1408524. doi: 10.3389/fonc.2024.1408524

Current landscape of primary small bowel leiomyosarcoma: cases report and a decade of insights

Junjie Zhou 1,, Houyun Xu 1,, Jibo Hu 1,*, Qiang Hong 2, Xiping Yu 3, Wei Liu 1, Jiaxin Zhao 2, Hongjie Hu 4,*
PMCID: PMC11153743  PMID: 38846972

Abstract

The incidence of leiomyosarcoma (LMS) is about 4–5/100,000 individuals per year. LMSs occurring in the small bowel are even rarer, and their preoperative diagnosis is very difficult. We described two patients with pathologically confirmed small bowel LMS and analyzed their clinical and medical imaging features. Similar cases reported in English in Pubmed database over the past decade were reviewed and summarized. These tumors were categorized by the growth direction and relationship with the intestinal lumen into three types: intraluminal (n = 10), intermural (n = 3), and extraluminal (n = 7). Notably, among the three types of LMS, the intramural leiomyosarcoma stands out as a noteworthy subtype. Emerging evidence suggests that smaller tumor size (< 5 cm) and the intraluminal type may serve as favorable prognostic indicators, while the extraluminal type is associated with relatively poor prognosis. Furthermore, the integration of imaging features with CA125 and LDH biomarkers holds promise for potential diagnostic value in LMS.

Keywords: small bowel, leiomyosarcoma, subtype, preoperative diagnosis, surgical operation

Background

Adult-type soft tissue and visceral sarcomas, excluding gastrointestinal stromal tumors (GISTs), are considered to be rare neoplasms, with an estimated average incidence of 4–5 cases per 100,000 individuals per year in Europe. Leiomyosarcomas (LMSs) have an even lower incidence, with less than 1 case per 100,000 individuals per year (1). The incidence of primary LMS in the GI tract is estimated to be about 1/50 that of GIST (2). The absence of thorough radiological assessments or inaccurate interpretations of image characteristics can result in additional delays in diagnosing primary tumors of the small intestine (3). Nonetheless, patients with small bowel LMS typically present at the emergency department with nonspecific symptoms and insufficient examinations, posing a significant challenge for clinicians in preoperative diagnosis (46). The objective of this study was to review our instances of small bowel LMS, including a summary of small bowel LMS cases reported in the past ten years in the English language literature available on Pubmed.

Cases presentation

Case 1. On 5 January 2023, a 70-year-old male patient with a history of hypertension and depression was referred to the emergency department with a complaint of abdominal pain in the lower abdomen which occurred 1 day ago. He denied any other accompanying symptoms like nausea, vomiting, melena, or hematochezia. Over the past several months, he developed a palpable, enlarging abdominal mass. Physical examination demonstrated a palpable mass with tenderness in the right lower abdomen. The patient has a body mass index (BMI) of 19.1 kg/m2, and has a smoking history of 40 years, consuming 10 cigarettes per day. He denies any history of alcohol consumption and reports no family history of cancer. A review of the laboratory examination of our patient revealed relevant abnormal indicators as shown in  Table 1 . An abdominal CECT revealed a lobulated, heterogeneously enhancing mass with fibrous separation and extensive necrosis originating from the terminal ileum measuring 8.7×7.0cm ( Figure 1 ), accompanied by a blurring of the adipose space and compression of the neighboring intestinal canal. Calcifications were observed at the periphery of the exophytic mass. The CT value of the solid component measured 58 Hounsfield Units (HU) before enhancement and 69 HU during the arterial phase. Maximum intensity projection of axial CECT scan in the arterial phase demonstrates the tumor’s blood supply originating from the superior mesenteric artery. Both radiologists and surgeons concur that the likely diagnosis is GIST. The patient underwent a right hemicolectomy on 10 January 2023, which showed that the tumor was seen on the side of the small bowel in the ileocecum, involving the bladder wall. The mass was adherent to the surrounding small intestine and mesentery. The proximal small intestine was edematous and dilated. Intraoperative blood loss was 100 ml and there were no intraoperative complications. Gross examination showed a large white hemorrhagic lesion with a 0.5 cm-sized perforation ( Supplementary Figure S1 ). Histopathological examination showed mitotically active spindle-shaped cells with severe diffuse atypia and abundant eosinophilic cytoplasm (16 mitoses per 10 high power fields) ( Figure 2A ). Fibrous septa and large areas of coagulative necrosis were seen inside the tumor ( Figure 2B ). Immunohistochemical staining was positive for caldesmon, desmin, and smooth muscle actin (SMA), but negative for CD117, DOG1, CD34, and S-100 ( Figures 2C–I ). Finally, the patient has confirmed the diagnosis of low differentiated leiomyosarcoma with negative surgical margins and negative lymph nodes. No lymphovascular or perineural invasion was observed. Ki-67 proliferation index was 50%.

Table 1.

Review of the laboratory test data of case one.

Preoperative F/U 1 month F/U 2 month Reference
CA-125 (U/mL) 45.18↑ 17.3 14.93 <24.0
CYFRA21-1 (ng/mL) 4.19↑ 1.27 1.04 <2.08
NSE (ng/mL) 25.61↑ 13.72 13.07 <25.00
LDH (U/L) 306↑ 180 191 120-250
D-Dimer (mg/L) 2.5↑ 1.89↑ 1.93↑ <0.5
CRP (mg/L) 52.1↑ 36↑ 11↑ 0-6

CA-125, carbohydrate antigen 125; CYFRA21-1, cytokeratins 19 fragment antigen21-1; NSE, neuron specific enolase; LDH, lactate dehydrogenase; CRP, C-reactive protein; F/U, follow-up.

↑, higher than reference value.

Figure 1.

Figure 1

Abdominal contrast-enhanced computed tomography of case one. (A) Plain scan shows a large heterogeneous mass (*) with calcification (red solid arrow) at the margins at the end of the ileum measuring 8.7×7.0 cm; (B) Adjacent bowels are pushed by the exophytic, heterogeneous enhanced mass; (C) The artery supplying blood to the mass is from a branch of the superior mesenteric artery and a tortuous draining vein is seen (yellow arrow); (D) Free gas in the abdominal cavity (red hollow arrow).

Figure 2.

Figure 2

Pathological examination of case one. (A) The tumor with mitotically active spindle-shaped cells with severe diffuse atypia and abundant eosinophilic cytoplasm (16 mitoses per 10 high power fields) (H&E, ×400). (B) Fibrous septa and large areas of coagulative necrosis within the tumor (H&E, ×40). The tumor cells express (C) Desmin, (D) smooth muscle actin (SMA), and (E) Caldesmon while other markers, (F) DOG1, (G) CD117, (H) CD34, and (I) S-100 are negative (H&E, ×100).

Postoperatively, he was treated with symptomatic support, and finally discharged without complications on the 15th postoperative day. Epirubicin-based treatment was scheduled by the oncologist. In October 2023, a CECT scan showed a tumor recurrence involving the rectus abdominis muscle. Gastrointestinal perforation occurred during hospitalization and he eventually died of infectious shock. Case 2. A 66-year-old man presented with abdominal pain and diarrhea for 7 months. 7 months ago, he was diagnosed with invasive adenocarcinoma lung cancer and received radical surgery. His BMI was 24.1 kg/m2. He had been smoking 30 cigarettes per day for the past 40 years, along with consuming 200 ml of white wine daily for 30 years. He denied any family history of cancer. Before this admission, he had undergone abdominal CECT which found a 4.8×4.2 cm tumor originating from the horizontal part of the duodenum. Laboratory examinations showed all results within normal limits except for cytokeratins 19 fragment antigen21–1 2.11 ng/mL (normal range < 2.08 ng/mL). The patient underwent segmental duodenal resection on March 20, 2023, with intraoperative blood loss of 20 ml. There were no intraoperative or postoperative complications, and the patient was discharged on the 7th postoperative day. Histology confirmed that the tumor was immunohistochemically positive for SMA, and desmin, while CD34, CD117, and DOG1 were negative ( Supplementary Figure S2 ). The final diagnosis of the tumor was a well-differentiated duodenal LMS. Ki-67 proliferation index was 30%. Surgical margins and lymph nodes were negative. No indications of lymphovascular or perineural invasion detected. There were no significant signs of recurrence in the operated area and other organs on abdominal CECT in the 7-month follow-up.

Discussion

To gain a comprehensive understanding of small bowel LMSs from various perspectives, we have compiled the characteristics of patients reported in the last decade, focusing solely on English language literature available on Pubmed. Based on the growth direction and relationship with the intestinal lumen, the LMSs can be categorized into three types: a) intraluminal, characterized by predominant luminal growth patterns; b) extraluminal, where growth extends beyond the intestinal lumen into adjacent tissues; and c) intramural, which exhibits infiltrative growth along the intestinal wall, resulting in thickening of the intestinal wall as the primary manifestation. Table 2 provides a comprehensive overview of the last decade reported cases of small bowel LMS (n = 20), categorized by survival duration. The age ranged from 38 to 90 years, with a median of 69.5 years. Of the total cases, 16 were male and 6 were female. The most prevalent symptom was abdominal pain, followed by weight loss, intestinal obstruction, gastrointestinal bleeding, and anemia. Additionally, non-specific gastrointestinal symptoms such as nausea and vomiting may manifest in the early stages of the disease. Among the identified tumors, 2 were located in the duodenum, 5 in the jejunum, 1 in the duodenal-jejunal junction, and 12 in the ileum. 2 of which have no site of origin mentioned. The average size of the tumors was 8.2 cm (range, 1.6–15 cm). A lobulated heterogeneous mass was the most common appearance in imaging findings, followed by intussusception, perforation, calcification, and thickened intestinal walls. Most of the cases underwent surgical resection, out of 16 patients with available data, 37.5% (6/16) underwent laparoscopic surgery while 62.5% (10/16) underwent laparotomy surgery. Mitotic figures ranged from 2 to 50 per 10 HPFs. SMA, desmin, and caldesmon are positive in LMSs at most times, while other markers CD117, CD34, DOG1, S-100 are negative. A total of 20 patients were grossly typed in all 22 cases (Intraluminal = 10; Intramural = 3; Extraluminal = 7). Statistical analysis of the characteristics between the different types is shown in Supplementary Table S1 . Among the 6 patients who survived for 12 months or longer, gross assessment was conducted on 5 of them. 4 out of the 5 patients (4/5) had intraluminal tumors, and 3 out of the 4 patients (3/4) remained disease-free at the end of the follow-up period. The average tumor size among the five patients was 5.28 cm. Among the 10 patients with a survival time of less than 12 months, 9 were available for gross assessment. Out of these 9 patients, 4 of them had intraluminal tumors (4/9), and one died from a different disease while the others showed no evidence of disease. Among the remaining 5 cases with an extraluminal growth pattern, three patients had died, and the average size of the extraluminal tumors was 10.8 cm. Despite the small bowel comprising 75% of the length and 90% of the absorptive mucosal surface of the gastrointestinal tract, the occurrence of malignant tumors originating from the small intestine is less than 5% (24, 25). Our study revealed a higher prevalence of primary small bowel LMSs in males, particularly in their sixties. These LMSs commonly manifest as an acute abdomen, resulting from complications such as intussusception, intestinal obstruction, and GI bleeding. Consequently, patients with LMSs often require admission to the emergency department. Among the small bowe segments, the ileum exhibits the highest incidence of LMSs, followed by the jejunum and duodenum. Interestingly, our study revealed that, in addition to extraluminal and intraluminal growth patterns, the intramural type of growth has also been documented as diffuse thickening of the intestinal wall, resembling the aneurysmal dilatation that is a characteristic imaging feature of lymphoma. The smooth muscle cells originating from the muscularis mucosa or propria, which are responsible for the development of LMSs, typically consist of elongated cells. (26) This observation may explain the lymphoma-like behavior exhibited by LMSs. In cases where the tumor exhibits a mitotic activity exceeding 10 per 10 high-power fields, the presence of invasive behavior becomes apparent (27). However, our study is currently unable to provide substantial support for this perspective due to limitations in available information. Despite the scarcity of clinical data, the observed trend suggests that smaller tumor size (< 5 cm) and the intraluminal type may serve as favorable prognostic factors. Regrettably, our evaluation did not encompass intramural LMSs. In the first case, a patient was admitted due to the manifestation of paroxysmal abdominal pain exclusively. Upon postoperative re-examination of the images, a minute presence of free gas within the abdominal cavity was observed ( Figure 1D ). To the best of our knowledge, the intestinal perforation observed in this particular case represents the fourth reported instance since the World Health Organization’s refinement of LMS (7, 18, 28). In the second case, the patient initially received treatment for lung cancer, and his laboratory tests indicate relatively normal results. The final diagnosis of LMS of the duodenum may have been fortuitous. The detection rates of LMSs are relatively low when using colonoscopy and esophagogastroduodenoscopy (16). Our current understanding of the imaging characteristics of LMS is limited due to the rarity of observing small bowel LMSs and the inadequacy of examinations. However, abdominal CECT still proves to be relatively effective in identifying lesions, although distinguishing between LMSs and GISTs can be challenging. A size exceeding 6 cm and the existence of irregular margins, with or without peripheral lymphadenopathy, indicate a considerable likelihood of malignancy, specifically either a GIST or the less common LMS (29). Goto et al. have mentioned that the combination of contrast-enhanced dynamic MRI with serum LDH levels has demonstrated a specificity, positive predictive value, negative predictive value, and diagnostic accuracy of 100% in distinguishing uterine leiomyosarcomas from degenerated leiomyomas (30). Zak et al. conducted a comprehensive review of multiple studies investigating the potential correlation between clinical indicators, including D-dimer, CRP, CA125, LDH, among others, and the presence of uterine LMSs for preoperative identification (31). However, it is important to note that abnormal tumor markers are relatively infrequent in small bowel LMSs (1517). Furthermore, there is currently no consensus regarding the role of CA125 in the diagnosis of LMSs. Nevertheless, when combined with imaging features, elevated levels of serum CA125 and LDH may contribute to the accurate diagnosis of LMSs. In our case, an MRI was not performed due to the emergency department procedure, however, the CECT in combination with laboratory indicators may have a potential diagnostic value of LMSs. Given the rarity of small bowel LMS, the absence of specific guidelines necessitates that surgical excision with negative margins (R0) remains the primary treatment objective (7). LMSs infrequently exhibit lymph node metastases, thus advanced lymph node dissection is typically unnecessary during these procedures (10). It is noteworthy that abdominal wall muscle involvement was detected in the three patients who experienced tumor recurrence, and laparotomy was employed as the surgical approach for all three patients (No1, 8; our case 1). Laparoscopic resection, which is less invasive, is considered a viable alternative to laparotomy (10). Neoadjuvant and adjuvant chemotherapy may be considered the preferred treatment option following a personalized multidisciplinary assessment, despite the lack of established efficacy and general recommendation (1).

Table 2.

Summary of small bowel leiomyosarcoma over the past decade reported cases arranged by length of survival.

No. Age/sex Clinical manifestations Site Size (cm) Imaging findings Surgery Gross Mitoses/10 HPFs Immunohistochemistry Outcome Survival (mo)
1 (7) 79y/F Intestinal obstruction Ileum NM Recurrence (Ileum, colon, and abdominis muscle) NM UE NM NM TR 64
2 (8) 38y/M GI bleed, weight loss Duodenum 1.6 Ulcerative hypodense lesion Laparotomy Intraluminal 21 SMA+, desmin+, CD117-, CD34-, DOG1-, S-100- ANED 32
3 (7) 83y/F Abd pain, intestinal obstruction Jejunum 5 Mass and jejunal invagination Laparoscopy Intraluminal NM SMA+, caldesmon+, desmin+, CD117-, CD34-, S100- DOD 15
4 (9) 54y/M Anemia Jejunum 10 Intussusception Laparoscopy Intraluminal >20 SMA+, caldesmon+, CD117-, CD34-, DOG1-, S-100- ANED 12
5 (10) 87y/M Abd pain, weight loss Jejunum 5 No evidence of tumor Laparoscopy Intraluminal 28 SMA+, CD117-, CD34-, S100- ANED 12
6 (11) 80y/M Abd pain, anemia Ileum 4.8 Intussusception Laparotomy Intraluminal NM Caldesmon+, desmin+, CD117-, DOG1- ANED 12
7 (7) 86y/M Intestinal obstruction Ileum 12 Pulmonary and mesenteric root metastasis NP Extraluminal NM SMA+, caldesmon+, desmin+, CD117-, CD34-, S100 DDD 11
8 (7) 69y/M Peritonitis Ileum NM Recurrence (Ileum, caecum) NM UE NM NM TR 7
9 (12) 45y/F Abd pain Ileum 8 Heterogeneous mass Laparoscopy Intraluminal 2-4 SMA+, desmin+, CD117-, CD34- ANED 6
10 (13) 65y/M Abd pain Ileum 6.5 Lobulated heterogeneous mass Laparotomy Extraluminal NM Caldesmon+, desmin+, CD117-, DOG1- ANED 4
11 (14) 80y/M Abd pain Ileum 3.5 Intussusception Laparoscopy Intraluminal 40 SMA+, desmin+, CD117-, DOG1-, S-100- DDD 3
12 (15) 43y/F Peritonitis Ileum 14.7 Perforation Laparotomy Extraluminal 40-50 SMA+, desmin+, CD117-, CD34-, DOG1-, S-100- ANED 2
13 (16) 67y/M Distended veins, weight loss NM 12 Lobulated heterogeneous mass Hepatic masses NP Extraluminal NM SMA+, desmin+, CD117-, DOG1- DOD 2
14 (17) 90y/M Abd pain Ileum 13 Intussusception Laparotomy Intraluminal NM SMA+, desmin+, CD117-, CD34-, DOG1-, S-100- ANED NM
15 (18) 66y/M Abd pain Jejunum 15 Perforation Laparotomy Intramural NM SMA+, desmin+, CD117-, CD34-, DOG1-, S-100- NM NM
16 (19) 62y/F GI bleed Ileum 9 Exophytic mass with calcifications Laparotomy Extraluminal 5-10 SMA+, caldesmon+, desmin+, CD117-, CD34-, DOG1-, S-100- ANED NM
17 (20) 72y/M Abd pain, weight loss, and GI bleed Jejunum 7 Thickened intestinal wall NM Intramural 8 SMA+, desmin+, CD117-, CD34-, DOG1- NM NM
18 (21) 72y/M Abd pain DJJ 7 Asymmetric luminal dilation and wall thickening NM Intramural NM SMA+, caldesmon+, desmin+, CD117-, CD34-, DOG1-, S-100- NM NM
19 (22) 45y/F Abd pain Ileum NM Intussusception Laparotomy Intraluminal 34 SMA+, desmin+ NM NM
20 (23) 83y/M Anemia NM NM Lobulated heterogeneous mass Laparotomy Extraluminal NM SMA+, caldesmon+, desmin+, CD117-, CD34-, S100- ANED NM
21 70y/M Abd pain Ileum 8.7 Perforation and calcification Laparotomy Extraluminal 16 SMA+, caldesmon+, desmin+, CD117-, CD34-, DOG1-, S-100- DOD 9
22 66y/M Abd pain Duodenum 4.8 Heterogeneous mass Laparoscopy Intraluminal 7-8 SMA+, desmin+, CD117-, CD34-, DOG1- ANED 7

ANED, alive, no evidence of disease; DDD, dead of different disease; DJJ, duodenal–jejunal junction; DOD, dead of disease; NM, not mentioned; NP, not performed; SMA, smooth muscle actin; TR, tumor recurrence; UE, unable to evaluate.

Conclusion

Based on our comprehensive literature review and extensive experience, the classification of LMS encompasses three distinct types: intraluminal, intermural, and extraluminal. Notably, intramural leiomyosarcoma stands out as a noteworthy subtype. Emerging evidence suggests that smaller tumor size (< 5 cm) and the intraluminal type may serve as favorable prognostic indicators, while the extraluminal type is associated with relatively poor prognosis. Furthermore, the integration of imaging features with CA125 and LDH biomarkers holds promise for potential diagnostic value in LMS.

Data availability statement

The original contributions presented in the study are included in the article/ Supplementary Material , further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving humans were approved by The Ethics Committee of The Fourth Affiliated Hospital, Zhejiang University School of Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

JuZ: Writing – original draft, Writing – review & editing. HX: Writing – original draft, Writing – review & editing. JH: Writing – original draft, Writing – review & editing, Conceptualization, Supervision. QH: Writing – original draft, Writing – review & editing. XY: Writing – original draft, Writing – review & editing. WL: Writing – original draft, Writing – review & editing. JiZ: Writing – original draft, Writing – review & editing. HH: Writing – original draft, Writing – review & editing.

Funding Statement

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Grant 82071988 from National Natural Science Foundation of China, Grant 2019C03064 from Key Research and Development Program of Zhejiang Province.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2024.1408524/full#supplementary-material.

DataSheet_1.docx (2.7MB, docx)

References

  • 1. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. (2021) 32:1348–65. doi:  10.1016/j.annonc.2021.07.006 [DOI] [PubMed] [Google Scholar]
  • 2. Yamamoto H, Handa M, Tobo T, Setsu N, Fujita K, Oshiro Y, et al. Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours. Histopathology. (2013) 63:194–207. doi:  10.1111/his.12159 [DOI] [PubMed] [Google Scholar]
  • 3. Masselli G, Guida M, Laghi F, Polettini E, Gualdi G. Magnetic resonance of small bowel tumors. Magnetic Resonance Imaging Clinics North America. (2020) 28:75–88. doi:  10.1016/j.mric.2019.08.005 [DOI] [PubMed] [Google Scholar]
  • 4. Anzidei M, Napoli A, Zini C, Kirchin MA, Catalano C, Passariello R. Malignant tumours of the small intestine: a review of histopathology, multidetector CT and MRI aspects. BJR. (2011) 84:677–90. doi:  10.1259/bjr/20673379 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Turan M, Karadayi K, Duman M, Özer H, Arici S, Yildirir C, et al. Small bowel tumors in emergency surgery. Ulus Travma Acil Cerrahi Derg. (2010) 16:327–33. [PubMed] [Google Scholar]
  • 6. Catena F, Ansaloni L, Gazzotti F, Gagliardi S, Di Saverio S, De Cataldis A, et al. Small bowel tumours in emergency surgery: specificity of clinical presentation. ANZ Surg. (2005) 75:997–9. doi:  10.1111/j.1445-2197.2005.03590.x [DOI] [PubMed] [Google Scholar]
  • 7. Ferrari C, Di Domenico S, Mascherini M, Santoliquido M, Mastracci L, De Cian F. Recurrent leiomyosarcoma of the small bowel: A case series. Anticancer Res. (2020) 40:4199–204. doi:  10.21873/anticanres.14420 [DOI] [PubMed] [Google Scholar]
  • 8. Hong SM, Kim GH, Kim D, Lee S. Duodenal leiomyosarcoma presenting with gastrointestinal bleeding and obstruction: A case report. Korean J Gastroenterol. (2020) 75:94. doi:  10.4166/kjg.2020.75.2.94 [DOI] [PubMed] [Google Scholar]
  • 9. Nakamura K, Shibasaki S, Yamada S, Suzuki K, Serizawa A, Akimoto S, et al. Totally laparoscopic resection using delta-shaped anastomosis of jejunal leiomyosarcoma with intussusception at the angle of Treitz: a case report. Surg Case Rep. (2022) 8:180. doi:  10.1186/s40792-022-01541-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Guzel T, Mech K, Mazurkiewicz M, Dąbrowski B, Lech G, Chaber A, et al. A very rare case of a small bowel leiomyosarcoma leading to ileocaecal intussusception treated with a laparoscopic resection: a case report and a literature review. World J Surg Onc. (2016) 14:48. doi:  10.1186/s12957-016-0798-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Štor Z, Hanžel J. Ileal leiomyosarcoma presenting with intussusception. J Surg Case Rep. (2019) 2:1–3. doi:  10.1093/jscr/rjz052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Hamm JK, Chaudhery SI, Kim RH. Laparoscopic resection of small bowel sarcoma. Surg Laparoscopy Endoscopy Percutaneous Techniques. (2013) 23:e138–40. doi:  10.1097/SLE.0b013e318280638e [DOI] [PubMed] [Google Scholar]
  • 13. Bouassida M, Beji H, Chtourou MF, Nechi S, Chaabane A, Touinsi H. Leiomyosarcoma of the small bowel: A case report and literature review. Int J Surg Case Rep. (2022) 97:107456. doi:  10.1016/j.ijscr.2022.107456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Kim H-G, Yang JW, Hong S-C, Ju Y-T, Jeong C-Y, Kim J-Y, et al. Ileocolonic intussusception caused by epithelioid leiomyosarcoma of the ileum: a report of case and review of the literature. Ann Coloproctol. (2022) 38:176–80. doi:  10.3393/ac.2020.12.08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Fawaz M, Kataria K, Singh A, Samadder S. Small intestine leiomyosarcoma mimicking gastrointestinal stromal tumour. BMJ Case Rep. (2021) 14:e244381. doi:  10.1136/bcr-2021-244381 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Abou El Joud K, Abbasi M. Lower extremity varicose veins: an unusual presentation of small bowel leiomyosarcoma. Gastrointest Tumors. (2022) 9:1–4. doi:  10.1159/000520802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Mazzotta E, Lauricella S, Carannante F, Mascianà G, Caricato M, Capolupo GT. Ileo-ileal intussusception caused by small bowel leiomyosarcoma: A rare case report. Int J Surg Case Rep. (2020) 72:52–5. doi:  10.1016/j.ijscr.2020.05.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Fukai S, Lefor AK, Nishida K. Perforation of intestinal leiomyosarcoma: A case report. Int J Surg Case Rep. (2021) 79:327–30. doi:  10.1016/j.ijscr.2021.01.062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Tolman CJ. A rare case of small bowel leiomyosarcoma presenting with acute gastro-intestinal bleeding. BJR|case Rep. (2017) 3:20160089. doi:  10.1259/bjrcr.20160089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Elhence PA, Rao M, Vishnoi JR, Meena V. Jejunal leiomyosarcoma: Report of a rare case diagnosed on cytology. Diagn Cytopathology. (2019) 47:498–502. doi:  10.1002/dc.24136 [DOI] [PubMed] [Google Scholar]
  • 21. Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, Hornick JL, et al. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. (2014) 39:33–9. doi:  10.1007/s00261-012-9904-4 [DOI] [PubMed] [Google Scholar]
  • 22. Niraj G, Richards CJ. Leiomyosarcoma of the small intestine presenting as abdominal myofascial pain syndrome (AMPS): case report. Scandinavian J Pain. (2021) 21:191–3. doi:  10.1515/sjpain-2020-0099 [DOI] [PubMed] [Google Scholar]
  • 23. Luis J, Ejtehadi F, Howlett DC, Donnellan IM. Leiomyosarcoma of the small bowel: Report of a case and review of the literature. Int J Surg Case Rep. (2015) 6:51–4. doi:  10.1016/j.ijscr.2014.11.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. (2009) 249:63–71. doi:  10.1097/SLA.0b013e31818e4641 [DOI] [PubMed] [Google Scholar]
  • 25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. (2008) 58:71–96. doi:  10.3322/CA.2007.0010 [DOI] [PubMed] [Google Scholar]
  • 26. Hilal L, Barada K, Mukherji D, Temraz S, Shamseddine A. Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis. Med Oncol. (2016) 33:20. doi:  10.1007/s12032-016-0730-3 [DOI] [PubMed] [Google Scholar]
  • 27. Jideh B, Yang T, Turner I. Rectal bleeding due to leiomyosarcoma. Clin Gastroenterol Hepatol. (2017) 15:e1–2. doi:  10.1016/j.cgh.2016.08.008 [DOI] [PubMed] [Google Scholar]
  • 28. Saylam B, Özozan ÖV, Düzgün AP, Külah B, Han Ö, Coşkun F. Perforated intestinal leiomyosarcoma as a metastasis of uterine leiomyosarcoma: a case report. Cases J. (2009) 2:9288. doi:  10.4076/1757-1626-2-9288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Williams EA, Bowman AW. Multimodality imaging of small bowel neoplasms. Abdom Radiol. (2019) 44:2089–103. doi:  10.1007/s00261-019-01955-y [DOI] [PubMed] [Google Scholar]
  • 30. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer. (2002) 12:354–61. doi:  10.1046/j.1525-1438.2002.01086.x [DOI] [PubMed] [Google Scholar]
  • 31. Żak K, Zaremba B, Rajtak A, Kotarski J, Amant F, Bobiński M. Preoperative differentiation of uterine leiomyomas and leiomyosarcomas: current possibilities and future directions. Cancers. (2022) 14:1966. doi:  10.3390/cancers14081966 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

DataSheet_1.docx (2.7MB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/ Supplementary Material , further inquiries can be directed to the corresponding author/s.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES